Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 6, 2006, Pages 540-548

  Toornvliet, Rolf ^a,b,c   van Berckel, Bart N M ^a,b,c   Luurtsema, Gert ^a,b,c   Lubberink, Mark ^a,b,c   Geldof, Albert A ^a,b,c   Bosch, Tessa M ^a,b,c   Oerlemans, Ruud ^a,b,c   Lammertsma, Adriaan A ^a,b,c   Franssen, Eric J F ^a,b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; DRUG METABOLITE; GLYCOPROTEIN P; TRACER; UNCLASSIFIED DRUG; VERAPAMIL C 11;

ADULT; AGED; AGING; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; GRAY MATTER; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LEUKOCYTE; MALE; NORMAL HUMAN; PERIPHERAL NERVOUS SYSTEM; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; AGED; AGING; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; FEMALE; GENOTYPE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; VERAPAMIL;

EID: 33744936006     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.02.004     Document Type: Article

References (39)

1. Gloor S.M., Wachtel M., and Bollinger M.F. Molecular and cellular permeability control at the blood-brain barrier. Brain Res Rev 36 (2001) 258-264
2. Ballabh P., Braun A., and Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16 (2004) 1-13
3. Sun H., Dai H., Shaik N., and Elmquist W.F. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55 (2003) 83-105
4. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., et al. Disruption of the mouse MDR1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
5. Pauli-Magnus C., Feiner J., Brett C., Lin E., and Kroetz D.L. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effect. Clin Pharmacol Ther 74 (2003) 487-498
6. Drozdik M., Bialecka M., Mysliwiec K., Honczarenko K., Stankiewicz J., and Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene. a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13 (2003) 259-263
7. Furuno T., Landi M., Ceroni M., Caporaso N., Bernucci I., Nappi G., et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12 (2002) 529-534
8. Gorell J.M., Peterson E.L., Rybicki B.A., and Johnson C.C. Multiple risk factors for Parkinson's disease. J Neurol Sci 15 (2004) 169-174
9. Kortekaas R., Leenders K.L., van Oostrom J.C.H., Vaalburg W., Bart J., Willemsen A.T.M., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
10. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12 (2002) 535-541
11. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene. multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
12. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta. relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297 (2001) 1137-1143
13. Hendrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., Van der Graaf W.T., Willemsen A.T., et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124 (1998) 1413-1418
14. Sasongko L., Link M., Muzi M., Mankhoff D.A., Xiaodong Y., Collier A.C., et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77 (2005) 503-514
15. Bart J., Willemsen A.T., Groen H.J., van der Graaf W.T., Wegman T.D., Vaalburg W., et al. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage 20 (2003) 1775-1782
16. Luurtsema G., Molthoff C.F.M., Windhorst A.D., Keizer H., Boellaard R., Smit H., et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function. in vitro and in vivo evaluation. Nucl Med Biol 30 (2003) 747-751
17. 11C]verapamil for measuring the P-glycoprotein function with positron emission tomography. J Labelled Comp Radiopharm 45 (2002) 1199-1207
18. Brix G., Zaers J., Adam L.E., Bellemann M.E., Ostertag H., Trojan H., et al., National Electrical Manufacturers Association. Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med 38 (1997) 1614-1623
19. Boellaard R., van Lingen A., van Balen S.C., Hoving B.G., and Lammertsma A.A. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 28 (2001) 81-89
20. Luurtsema G., Molthoff C.F., Schuit R.C., Windhorst A.D., Lammertsma A.A., and Franssen E.J. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier. kinetics and metabolism in the rat. Nucl Med Biol 32 (2005) 87-93
21. 11C]verapamil PET data [abstract]. J Cereb Blood Flow Metab 25 (2005) S608
22. Smith S.M. Fast robust automated brain extraction. Hum Brain Mapp 17 (2002) 143-155
23. Oxford Centre for Functional Magnetic Resonance Imaging of the Brain. Available from: URL:www.fmrib.ox.ac.uk/fsl. Accessed May 4, 2006.
24. Maes F., Collignon A., Vandermeulen D., Marchal G., and Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16 (1997) 187-198
25. Catholic University, Leuven, Belgium. Medical image computing. Available from: URL:www.medicalimagecomputing.com. Accessed May 4, 2006.
26. Zhang Y., Brady M., and Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 20 (2001) 45-57
27. Machado C.G., Calado R.T., Garcia A.B., and Falcao R.P. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Braz J Med Biol Res 36 (2003) 1653-1657
28. Vasquez E.M., Petrenko Y., Jacobssen V., Sifontis N.M., Testa G., Sankary H., et al. An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. Transplant Proc 37 (2005) 175-177
29. van der Pol M.A., Pater J.M., Feller N., Westra A.H., van Stijn A., Ossenkoppele G.J., et al. Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 15 (2001) 1554-1563
30. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., and van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28 (1990) 495-503
31. Pauli-Magnus C., von Richter O., Burk O., Ziegler A., Mettang T., Eichelbaum M., et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 293 (2000) 376-382
32. Falcao R.P. Age-related changes of P-glycoprotein-mediated rhodamine 123 efflux in normal human bone marrow hematopoietic stem cells. Leukemia 17 (2003) 816-818
33. Warrington J.S., Greenblatt D.J., and von Moltke L.L. The effect of age on P-glycoprotein expression and function in the Fisher-344 rat. J Pharmacol Exp Ther 309 (2004) 730-736
34. Morita N., Yasumori T., and Nakayama K. Human MDR1 polymorphism. G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65 (2003) 1843-1852
35. Brunner M., Langer O., Sunder-Plaussmann R., Dobrozemsky G., Mueller U., Wadsak W., et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78 (2005) 182-190
36. Yanase D., Matsunari I., Yajima K., Chen W., Fujikawa A., Nisimura S., et al. Brain FDG PET study of normal aging in Japanese. effect of atrophy correction. Eur J Nucl Med Mol Imaging 32 (2005) 794-805
37. Aston J.A., Cunningham V.J., Asselin M.C., Hammers A., Evans A.C., and Gunn R.N. Positron emission tomography partial volume correction. estimation and algorithms. J Cereb Blood Flow Metab 22 (2002) 1019-1034
38. Rousset O.G., Ma Y., and Evans A.C. Correction for effects in PET. principle and validation. J Nucl Med 39 (1998) 904-911
39. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115 (2005) 3285-3290